A group M consensus envelope glycoprotein induces antibodies that neutralize subsets of subtype B and CHIV-1 primary viruses

被引:167
作者
Liao, Hua-Xin [1 ]
Sutherland, Laura L.
Xia, Shi-Mao
Brock, Mary E.
Scearce, Richard M.
Vanleeuwen, Stacie
Alam, S. Munir
McAdams, Mildred
Weaver, Eric A.
Camacho, Zenaido T.
Ma, Ben-Jiang
Li, Yingying
Decker, Julie M.
Nabel, Gary J.
Montefiori, David C.
Hahn, Beatrice H.
Korber, Bette T.
Gao, Feng
Haynes, Barton F.
机构
[1] Duke Univ, Sch Med, Duke Human Vaccine Inst, Durham, NC 27710 USA
[2] Duke Univ, Sch Med, Dept Med, Durham, NC 27710 USA
[3] Duke Univ, Sch Med, Dept Surg, Durham, NC 27710 USA
[4] NIAID, Vaccine Res Ctr, NIH, Bethesda, MD 20892 USA
[5] Univ Alabama Birmingham, Dept Med, Birmingham, AL 35203 USA
[6] Univ Alabama Birmingham, Dept Microbiol, Birmingham, AL 35203 USA
[7] Los Alamos Natl Lab, Los Alamos, NM 87545 USA
[8] Santa Fe Inst, Santa Fe, NM 87501 USA
关键词
HIV-1; vaccine; neutralization antibody; consensus inummogens;
D O I
10.1016/j.virol.2006.04.043
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
HIV-1 subtype C is the most common HIV-1 group M subtype in Africa and many parts of Asia. However, to date HIV-1 vaccine candidate immunogens have not induced potent and broadly neutralizing antibodies against subtype C primary isolates. We have used a centralized gene strategy to address HIV-1 diversity and generated a group M consensus envelope gene with shortened consensus variable loops (CON-S) for comparative studies with wild-type (WT) Env immunogens. Our results indicate that the consensus HIV-1 group M CON-S Env elicited cross-subtype neutralizing antibodies of similar or greater breadth and titer than the WT Envs tested, indicating the utility of a centralized gene strategy. Our study also shows the feasibility of iterative improvements in Env immunogenicity by rational design of centralized genes. (c) 2006 Published by Elsevier Inc.
引用
收藏
页码:268 / 282
页数:15
相关论文
共 58 条
[1]   An inducible HIV type 1 gp41 HR-2 peptide-binding site on HIV type 1 envelope gp120 [J].
Alam, SM ;
Paleos, CA ;
Liao, HX ;
Scearce, R ;
Robinson, J ;
Haynes, BF .
AIDS RESEARCH AND HUMAN RETROVIRUSES, 2004, 20 (08) :836-845
[2]  
André S, 1998, J VIROL, V72, P1497
[3]  
BARNDORFFNIELSE.OE, 2001, QUANTITATIVE FINANCE, V1, P1
[4]   Immunization with recombinant canarypox vectors expressing membrane-anchored glycoprotein 120 followed by glycoprotein 160 boosting fails to generate antibodies that neutralize R5 primary isolates of human immunodeficiency virus type 1 [J].
Bures, R ;
Gaitan, A ;
Zhu, TF ;
Graziosi, C ;
McGrath, KM ;
Tartaglia, J ;
Caudrelier, P ;
EL Habib, R ;
Klein, M ;
Lazzarin, A ;
Stablein, DM ;
Deers, M ;
Corey, L ;
Greenberg, ML ;
Schwartz, DH ;
Montefiori, DC .
AIDS RESEARCH AND HUMAN RETROVIRUSES, 2000, 16 (18) :2019-2035
[5]   Modifications of the human immunodeficiency virus envelope glycoprotein enhance immunogenicity for genetic immunization [J].
Chakrabarti, BK ;
Kong, W ;
Wu, B ;
Yang, ZY ;
Friborg, J ;
Ling, X ;
King, SR ;
Montefiori, DC ;
Nabel, GJ .
JOURNAL OF VIROLOGY, 2002, 76 (11) :5357-5368
[6]   Selection for human immunodeficiency virus type I envelope glycosylation variants with shorter V1-V2 loop sequences occurs during transmission of certain genetic subtypes and may impact viral RNA levels [J].
Chohan, B ;
Lang, D ;
Sagar, M ;
Korber, B ;
Lavreys, L ;
Richardson, B ;
Overbaugh, J .
JOURNAL OF VIROLOGY, 2005, 79 (10) :6528-6531
[7]   Sensitivity of human immunodeficiency virus type 1 to the fusion inhibitor T-20 is modulated by coreceptor specificity defined by the V3 loop of gp120 [J].
Derdeyn, CA ;
Decker, JM ;
Sfakianos, JN ;
Wu, XY ;
O'Brien, WA ;
Ratner, L ;
Kappes, JC ;
Shaw, GM ;
Hunter, E .
JOURNAL OF VIROLOGY, 2000, 74 (18) :8358-8367
[8]   Envelope-constrained neutralization-sensitive HIV-1 after heterosexual transmission [J].
Derdeyn, CA ;
Decker, JM ;
Bibollet-Ruche, F ;
Mokili, JL ;
Muldoon, M ;
Denham, SA ;
Heil, ML ;
Kasolo, F ;
Musonda, R ;
Hahn, BH ;
Shaw, GM ;
Korber, BT ;
Allen, S ;
Hunter, E .
SCIENCE, 2004, 303 (5666) :2019-2022
[9]   Induction of primary virus-cross-reactive human immunodeficiency virus type 1-neutralizing antibodies in small animals by using an alphavirus-derived in vivo expression system [J].
Dong, M ;
Zhang, PF ;
Grieder, F ;
Lee, J ;
Krishnamurthy, G ;
VanCott, T ;
Broder, C ;
Polonis, VR ;
Yu, XF ;
Shao, YM ;
Faix, D ;
Valente, P ;
Quinnan, GV .
JOURNAL OF VIROLOGY, 2003, 77 (05) :3119-3130
[10]   Human immunodeficiency virus type 1 subtype B ancestral envelope protein is functional and elicits neutralizing antibodies in rabbits similar to those elicited by a circulating subtype B envelope [J].
Doria-Rose, NA ;
Learn, GH ;
Rodrigo, AG ;
Nickle, DC ;
Li, F ;
Mahalanabis, M ;
Hensel, MT ;
McLaughlin, S ;
Edmonson, PF ;
Montefiori, D ;
Barnett, SW ;
Haigwood, NL ;
Mullins, JI .
JOURNAL OF VIROLOGY, 2005, 79 (17) :11214-11224